Low-Grade Serous Carcinoma of the Ovary

MeSH terms

• Angiogenesis Inhibitors / therapeutic use*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Bevacizumab / therapeutic use*
• Biomarkers, Tumor / blood*
• CA-125 Antigen / blood
• Cystadenocarcinoma, Serous* / blood
• Cystadenocarcinoma, Serous* / diagnosis
• Cystadenocarcinoma, Serous* / genetics
• Cystadenocarcinoma, Serous* / mortality
• Cystadenocarcinoma, Serous* / therapy
• Female
• Humans
• Membrane Proteins / blood
• Mutation
• Neoplasm Grading
• Neoplasm Recurrence, Local* / blood
• Neoplasm Recurrence, Local* / diagnosis
• Neoplasm Recurrence, Local* / genetics
• Neoplasm Recurrence, Local* / mortality
• Neoplasm Recurrence, Local* / therapy
• Neoplasm Staging
• Ovarian Neoplasms* / blood
• Ovarian Neoplasms* / diagnosis
• Ovarian Neoplasms* / genetics
• Ovarian Neoplasms* / mortality
• Ovarian Neoplasms* / therapy
• Ovariectomy
• Proto-Oncogene Proteins B-raf / blood
• Proto-Oncogene Proteins p21(ras) / blood
• Survival Analysis
• Treatment Outcome